Ellis-van Creveld syndrome, an autosomal recessively inherited chondrodysplastic dwarfism, is frequent among Old Order Amish of Pennsylvania. Decades of longitudinal research on bipolar affective disorder (BPAD) revealed cosegregation of high numbers of EvC and Bipolar I (BPI) cases in several large Amish families descending from the same pioneer. Despite the high prevalence of both disorders in these families, no EvC individual has ever been reported with BPI. The proximity of the EVC gene to our previously reported chromosome 4p16 BPAD locus with protective alleles, coupled with detailed clinical observations that EvC and BPI do not occur in the same individuals, led us to hypothesize that the genetic defect causing EvC in the Amish confers protection from BPI. This hypothesis is supported by a significant negative association of these two disorders when contrasted with absence of disease (P = 0.029, Fisher's exact test, two-sided, verified by permutation to estimate the null distribution of the test statistic). As homozygous Amish EVC mutations causing EvC dwarfism do so by disrupting sonic hedgehog (Shh) signaling, our data implicate Shh signaling in the underlying pathophysiology of BPAD. Understanding how disrupted Shh signaling protects against BPI could uncover variants in the Shh pathway that cause or increase risk for this and related mood disorders.
INTRODUCTION
Bipolar affective disorder (BPAD; manic-depressive illness) is a common psychiatric disorder with primary features of recurrence (cyclicity) and swings (polarity) from high to low of both mood and energy. Individuals with BPAD can shift from 'mania to melancholia' or from high affectivity and excitement to the profound low energy and sadness of depression. 1-3 BPAD affects 1-2% of the global population and is associated with a high risk of suicide. 3 Morbid risk analyses of BPAD demonstrate a high prevalence of affective disorder (especially BPI) among first-degree relatives of bipolar probands in the Amish Study families. 4 Because of the long-term, longitudinal nature of the Amish Study, the unaffected, mentally healthy (well individuals) in these families were also followed, most for a period of years past the age of risk for BPAD. Although sporadic cases of Ellis-van Creveld syndrome occur in many populations, EvC is frequent among the Old Order Amish (OOA) of Pennsylvania. 5 Unexpectedly, no EvC individual has ever been reported with BPI, despite more than 40 years of research documenting the cosegregation of EvC and BPI in the same extended pedigree and descending from the same pioneer.
Twin, family and adoption studies have all provided strong evidence for an important genetic component in the susceptibility to develop BPAD. 6, 7 However, unlike most common medical illnesses, objective biological markers have not been identified for BPAD, and genetic studies have had to rely on only clinical diagnoses. Despite compelling clinical-epidemiologic evidence supporting a significant genetic susceptibility to develop BPAD, identification of the genetic variants and an associated underlying molecular mechanism or pathophysiology have remained elusive. [8] [9] [10] [11] [12] [13] [14] Genetic heterogeneity, phenocopies, genotyping errors and the complexities of performing and interpreting statistical analyses may have contributed to some of the inconsistences observed in genetic studies. 6, 15 In 1998, we reported the results of a genome-wide search for chromosomal loci linked to mental health wellness in relatives at high risk for BPAD among the OOA. 16 We found strong evidence for a locus in the proximity of the EvC gene on chromosome 4p at D4S2949 (maximum GENEHUNTER-PLUS nonparametric linkage Score = 4.05, P = 5.22 × 10 − 4 ; SIBPAL empirical Po 3 × 10 − 5 ) and suggestive evidence for a locus on chromosome 4q at D4S397 (maximum GENEHUNTER-PLUS nonparametric linkage score = 3.29, P = 2.57 × 10 − 3 ; SIBPAL empirical P o 1 × 10 − 3 ; see Supplementary Figure S1 ). 16, 17 The genes for EVC and hedgehoginteracting protein (Hhip), a Shh antagonist, were subsequently cloned and found to be located within 5 million bases of our chromosome 4p16 (D4S2949) and 4q (D4S397) putative protective or susceptibility loci for BPAD, respectively.
Taken together, these observations led us to postulate that the molecular mechanism underlying EvC is protective against BPI. We now report clinical and statistical evidence that disruption of sonic hedgehog signaling in EvC confers protection from BPI and perhaps more generally against affective disorders. 
MATERIALS AND METHODS

EvC ascertainment and diagnosis
The current research on EvC syndrome began 50 years ago. 20 EvC families were ascertained systematically by Amish church districts. EvC subjects were examined and diagnosed at home or at the Johns Hopkins Moore Clinic in Baltimore, MD, USA. 20 Deceased were certified by death records. A pedigree trace was conducted for every EvC sibship. The resulting progenitor charts tested whether all Amish EvC cases descended from a common progenitor. At that time, the single existing OOA genealogy covered only two founders (Fisher and Stoltzfus). 21 It was coupled with archival materials, and subsequent research resulted in a large EvC pedigree that has been previously published. 20, 22 Drafting progenitor charts for EvC cases ascertained since the original research has benefited from the publication of a major genealogy that incorporates all present Amish families tracked along 26 different pioneer family lines. 23 
BPI ascertainment and diagnoses
The Amish Study on major affective disorders (1976-2014) has been conducted with annual IRB approval and multiple informed consents. 24 Details regarding ascertainment procedures, documentation of clinical materials and reliability of diagnoses have been published widely, including by the Coriell NIGMS Human Catalogue of Cell Lines. 25, 26 Two types of clinical data (psychiatric interviews and medical records) were processed for independent and 'blinded' assessment by a five-member Amish Study Psychiatric Board 26 using Research Diagnostic Criteria (RDC) 27 and Diagnostic Criteria from DSM-III-IV (DSM) 28 to make categorical diagnoses (see Table 1 ). After consensus diagnosis of BPI cases, their families became the basis of a large, multi-generational pedigree known as Amish Study BPAD PED.110/210/310/410.
RESULTS
EvC samples past and present
The original EvC study reported on 31 EvC sibships yielding 59 dwarfs (41 infant deaths and 18 living to maturity). 20 Currently, 28 of the original 31 EvC sibships have been updated and an additional 39 families recently ascertained. This doubled the original sample to 67 EvC families with 156 dwarfs, 33 surviving to adulthood. Among these 33 individuals with EvC were a number in the 40-70 years of age categories (67% over age 40 years; 52% over age 50 years) and past the window of risk for onset of BPI disorder. Our sample includes 21 nuclear families with one EvC dwarf, 22 with two, 11 with three, 7 with four and 6 families with five EvC dwarfs (total of 156 dwarfs). Data were also assembled regarding EvC features among the 'normal' relatives in the extended EvC families. Relatives were identified with a missing digit, toe, arm, foot or leg, as further evidence of the broad spectrum of skeletal dysplasia in EvC features for Amish families.
Cosegregation of EvC and BPI
Progenitor traces on confirmed BPI cases yielded the same pioneer, Koenig, identified previously as the progenitor for EvC and giving early evidence for significant cosegregation of these two illnesses. The individual progenitor traces for each EvC family determined their precise location on BPAD Master Pedigree 110/210/310/410 and resulted in a new Amish Study pedigree designated as EvC/BPAD Pedigree 800. Although the bipolar pedigree comprises 42 BPI sub-pedigrees, the EvC families were mainly included in four of them. (See Figure 1) . Apart from the documented cosegregation of EvC and BPI, case ascertainment spanning four decades did not reveal subjects with comorbidity.
Association analysis
Two types of association analysis were performed on all 358 individuals in the BPAD master pedigree for whom both EvC genotype and BPAD diagnosis were available: a Fisher's exact test, which ignores all relationships, and large sample tests based on a logistic regression that allowed for the familial dependencies. Only one primary hypothesis was tested, that of association between BPI/no disease status and EvC/no disease status; all other tests were exploratory and for these P-values are given with no correction for multiple tests. It is important to note that, although individuals were genotyped because of being related to BPADdiagnosed pedigree members, all individuals who were genotyped were included in the data, regardless of whether they had BPAD or not (BPAD disease/no disease status) when the sample for analysis was selected. Thus, no ascertainment bias could result from the way the sample was selected. The primary hypothesis attained significance (P = 0.029, Fisher's exact test, two-sided), verified by permutation to estimate the null distribution of the test statistic (see Supplementary Materials, especially Supplementary  Table S1 ). Most of the pairs of 285 pedigree members included in this test, as for all the 358 pedigree members, were unrelated at least up to third degree (see Supplementary Table S2 in Supplementary Materials). Mean age of onset, when known, was 20-30 for subcategories 1-4, 40 for subcategory 5 (see Table 1 and Supplementary Table S3 in Supplementary Materials). Tables (2 × 2) were then formed from individual and groups of BPAD disease/no disease subcategories (as defined in Supplementary Materials) and the two EvC classes of interest, namely carriers of two mutant alleles versus all others, and tested under various mixed effect logistic models as well as by Fisher's exact test. We performed these exploratory logistic regression analyses as implemented in the S.A.G.E program ASSOC (https://code.google.com/ p/opensage/), which differentiates the dependence of siblings from that of the parent-offspring relationship, allows for a spousal correlation and performs two different but asymptotically equivalent tests-Wald tests and likelihood ratio (LR) tests. Although the same P-value for testing the same null hypothesis does not guarantee that we can rely on the asymptotic test, different Pvalues automatically imply that the sample is not large enough for the asymptotic test to be reliable. The latter assumes no numerical inaccuracies, which might occur owing to computer limitations, but would not be relevant for the small number of significant digits we show in our tables. The regression analyses could thus detect a polygenic component of variance, as well as variance components attributable to effects common to spouses, common to siblings over and above that attributable to a polygenic effect, and/or individual-specific effects. The Wald and LR tests, unlike Fisher's exact test, are strictly valid only for large samples, but can be compared for samples of approximately the same size. 
DISCUSSION
The cosegregation of EvC and BPAD in our large, multigenerational Amish pedigree provided a rare, informative 'experiment of nature'. Decades of careful longitudinal tracking of EvC and BPAD cases in Amish families (same extended pedigree, descending from the same pioneer) led to our observation that through Supplementary Table S1 ), supported our hypothesis that EvC confers protection (that is, mental health wellness) from BPI, as well as suggesting a more general protection against the spectrum of affective disorders in these families (see Supplementary Materials, especially Supplementary  Tables S4 and S5 ). Attempts to confirm this association can be performed in large GWAS data sets, by restricting analyses to genes comprising or interacting with the Shh pathway. The significant association between absence of BPI and EvC, along with EvC causing disruption of Shh signaling and linkage evidence for protection/susceptibility genes for BPAD at the 4p EvC and 4q Hhip loci suggested the involvement of Shh signaling in mood disorders. To date, most genetic studies of affective disorders have been limited to identifying genetic variants that increase the risk of disease. 29 By contrast, we have previously provided evidence that, in addition to rare susceptibility alleles, there may be rare alleles that reduce the risk of developing BPAD in a manner similar to that reported for other complex inherited disorders. 16 Falsenegative genomic study findings could result when individuals inherit disease susceptibility alleles, but are misclassified because they do not manifest the phenotype due to the presence of protective alleles. 16, 17 Although the concept that rare protective alleles could modify (or even prevent) a behavioral phenotype like BPAD is relatively novel, several examples for non-psychiatric diseases have been reported. For instance, individuals in Limone sul Garda in Northern Italy were discovered to have Apo A-I MILANO , a rare mutant apolipoprotein that is associated with a reduced risk of atherosclerosis. 30 Among Ecuadorian villagers, the rare, autosomal recessively inherited Laron Syndrome (GHRD) dwarfism appears protective of diabetes and cancer due to reduced levels of insulin-like growth factor 1. [31] [32] [33] More recently, a rare mutation in the amyloid precursor protein gene has been shown to protect individuals from developing Alzheimer's disease. 34 Cosegregation of diseases that interact in this way is more likely to occur in a genetic isolate like the Amish, where there are limited numbers of founders.
Our earlier 1998 genome-wide linkage data suggested the presence of two loci with rare alleles protective of BPAD located on chromosome 4, one on 4p16 at D4S2949 and the other on 4q at D4S397, respectively (see Supplementary Figure S1 ). 16, 17 The proximity of the EVC gene to our previously reported chromosome 4p16 BPAD protective/susceptability locus, coupled with detailed clinical observations and statistical confirmation that EvC and BPI do not occur in the same Amish individuals, led us to consider that the genetic defect causing EvC in the Amish confers protection from BPI. The discovery that EvC is the result of disrupted Shh signaling focused our attention on the sonic hedgehog (Shh) signaling pathway (Figure 3 ). [35] [36] [37] [38] [39] The presence of a Shh antagonist gene, hedgehog-interacting protein (Hhip), at our BPAD chromosome 4q protection/susceptibility locus is additionally suggestive of Shh signaling involvement in BPAD.
The association of EvC and Shh pathway mutations has been mainly with a heterogeneous group of inherited skeletal disorders, 19 holoprosencephaly and a wide range of tumor growth, progression and metastasis. [40] [41] [42] [43] [44] [45] EvC syndrome in the Amish of Pennsylvania is the result of homozygous intron13 (IVS13 +5G4T) EVC gene mutations. 19 The clinical manifestations of EvC are diverse: some patients dying a few days after birth, while others live a long and active life. 18, 46 More recently, attention has focused on the importance of EVC and EVC2 in primary cilia signal transduction, structures enriched in key components of the Shhtransduction pathway, 36 controlling the kind, numbers and patterning of cells during development in many tissues, including the nervous system. 47 The correct localization and stoichiometry of EVC and EVC2 proteins as a complex in primary cilia are required for their normal function as positive modulators of the Shh pathway signaling. Lack of this normal EVC/EVC2 protein complex disrupts Shh signaling (Figure 3 ). 35, 37, 38 It is likely that the mechanism by which this homozygous mutation acts is by overriding abnormal Shh signaling to protect against appearance of BPAD disorder in these high-risk multigenerational pedigrees. Although hedgehog ligands encode signaling molecules in a wide range of tissues, sonic hedgehog (Shh) is the only hedgehog family member reported to be expressed in the mammalian central nervous system. [47] [48] [49] [50] [51] A growing body of evidence suggests that the state-like and oscillatory interactions of gene products within and extending from the Shh signaling pathway (Figure 3) , 49, 50, 52, 53 and modulated by environmental factors, could constitute the basis for the wide range of phenotypic manifestations of BPAD. [54] [55] [56] Antidepressant drugs, 57 including lithium, 58 and electroconvulsive therapy 59 have been shown to alter Shh signaling. Glycogen synthase kinase 3 (GSK3; GSK3α/GSK3β) is a target of lithium and has a central role in Shh signaling. 60 In addition to lithium, valproate, selective 5-HT reuptake inhibitors, monoamine oxidase inhibitors and tricyclic antidepressants have been shown to alter GSK3 activity. Studies on interactions between Shh and corticotropin-releasing hormone (CRH) signaling networks have related Shh signaling to neurotransmitter systems underlying anxiety, stress and depressive disorders. 61, 62 Cholesterol and palmitoic acid, required for appropriate Shh processing and long range signaling, [63] [64] [65] [66] [67] [68] have been associated with suicide, depression and BPAD. 69 Significantly more suicide attempters and completers have been reported among the biological relatives of Smith-Lemli-Opitz syndrome carriers, a population of individuals with reduced activity of 7-dehydrocholesterol reductase (DHCR7), an enzyme required for Shh processing. 70 Altered brain sterol composition, involving cholesterol, 7-dehydrocholesterol and/or 7-dehydrodesmosterol, has also been associated with a greater risk of suicidal behaviors. 70 Variants in EVC have recently been reported to be associated with male completed suicide. 71 Interestingly, the Amish Study ascertained OOA suicides (n = 26) for the period 1880-1990 and found that they were heavily clustered in PED 800, almost all were males with BPAD, equally divided between bipolar and major depression. 72 It is possible that BPAD, EvC and male suicide in these Amish Study families could be explained by genetic variants that influence Shh signaling. 73, 74 Our study of the cosegregation of EvC and BPAD in the Old Order Amish further implicates Shh signaling in the pathophysiology of BPAD and suggests that other genes/proteins in the Shh signaling pathway may be involved in protection or susceptibility to developing mood disorders. The increased understanding of the molecular basis of Shh signaling and reactivation occurring in a wide range of cancers has led to the identification of Shh signaling antagonists that are already in human clinical studies. 75 Repurposing of drugs targeting Shh signaling that are already in clinical development for other medical conditions could lead to better treatments for affective disorders in the near future.
